J INTS BIO, AACR 2023 - Presentation of preclinical study results of 'JIN-A04', an oral target therapy for HER2 exon insertion mutation NSCLC
PR NewswireApr 26, 2023
SEOUL, South Korea , April 26, 2023 /PRNewswire/ -- J INTS BIO announced the poster presentation of its novel, orally administered TKI 'JIN-A04' targeting NSCLC with HER2 exon 20 insertion mutation at the annual meeting of the American Association of Cancer Research 2023, which was held in Orlando , USA from April 14 to 19 . - Professor Cho,Byoung Chul is having a conversation about the...